Crinetics Pharmaceuticals (CRNX) Non-Current Deferred Tax Liability (2019 - 2024)

Crinetics Pharmaceuticals' Non-Current Deferred Tax Liability history runs 4 years deep, the most recent figure standing at $9.8 million for Q4 2024.

• In Q4 2024, Non-Current Deferred Tax Liability changed 0.49% year-over-year to $9.8 million; the TTM figure through Dec 2024 stood at $9.8 million (changed 0.49% YoY), while the FY2024 annual figure was $9.8 million, changed 0.49% from the prior year.
• Non-Current Deferred Tax Liability was $9.8 million for Q4 2024 at Crinetics Pharmaceuticals, roughly flat from $9.8 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $9.8 million in Q4 2023 to a low of $453000.0 in Q4 2022.
• Historically, Non-Current Deferred Tax Liability has averaged $6.7 million across 3 years, with a median of $9.8 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Non-Current Deferred Tax Liability soared 2063.13% in 2023, then dropped 0.49% in 2024.
• A 3-year view of Non-Current Deferred Tax Liability shows it stood at $453000.0 in 2022, then jumped by 2063.13% to $9.8 million in 2023, then dropped by 0.49% to $9.8 million in 2024.
• The last three Non-Current Deferred Tax Liability figures came in at $9.8 million (Q4 2024), $9.8 million (Q4 2023), and $453000.0 (Q4 2022), per Business Quant data.